Harvey R S, Reffitt D M, Doig L A, Meenan J, Ellis R D, Thompson R P, Powell J J
The Gastrointestinal Laboratory, The Rayne Institute, St Thomas' Hospital, London, UK.
Aliment Pharmacol Ther. 1998 Sep;12(9):845-8. doi: 10.1046/j.1365-2036.1998.00380.x.
Oral iron supplements, which are usually in the form of ferrous (Fe2+) salts, are toxic to the gastrointestinal mucosa, and so intolerance is common, resulting in poor compliance and failure of treatment. The sugar derivative maltol strongly chelates iron, rendering it available for absorption and stabilized in the less toxic ferric (Fe3+) form.
To test whether ferric trimaltol could correct iron deficiency anaemia in patients intolerant of ferrous sulphate.
Twenty-three patients were recruited from gastroenterology clinics, of whom 1 5 had inflammatory bowel disease, a group often difficult to treat with oral iron. Patients with iron deficiency anaemia and documented intolerance to ferrous sulphate were given 3 months of treatment with ferric trimaltol.
Nineteen of 23 patients completed the treatment and anaemia was fully corrected in 14 of these, mean haemoglobin increased from 106 +/- 15 to 126 +/- 16 g/L, and there was a particularly low incidence of side-effects. Of 11 patients with inflammatory bowel disease who completed the study, nine fully corrected their anaemia.
The results demonstrate that in patients intolerant of ferrous compounds, ferric trimaltol corrects iron deficiency and has a low incidence of side-effects.
口服铁补充剂通常为亚铁（Fe2+）盐形式，对胃肠道黏膜有毒性，因此不耐受情况常见，导致依从性差和治疗失败。糖衍生物麦芽酚能强烈螯合铁，使其易于吸收并以毒性较小的三价铁（Fe3+）形式稳定存在。
测试三麦芽酚铁能否纠正硫酸亚铁不耐受患者的缺铁性贫血。
从胃肠病诊所招募了23名患者，其中15名患有炎症性肠病，这是一组通常难以用口服铁剂治疗的患者。缺铁性贫血且有硫酸亚铁不耐受记录的患者接受了3个月的三麦芽酚铁治疗。
23名患者中有19名完成了治疗，其中14名贫血得到完全纠正，平均血红蛋白从106±15g/L增至126±16g/L，且副作用发生率特别低。在完成研究的11名炎症性肠病患者中，9名贫血得到完全纠正。
结果表明，对于亚铁化合物不耐受的患者，三麦芽酚铁可纠正缺铁且副作用发生率低。
